Clinical, Gut Microbial and Neural Effects of a Probiotic Add-On Therapy in Depressed Patients: A Randomized Controlled Trial Publisher Pubmed



Schaub AC¹ ; Schneider E¹ ; Vazquezcastellanos JF^{2, 3} ; Schweinfurth N¹ ; Kettelhack C¹ ; Doll JPK¹ ; Yamanbaeva G¹ ; Mahlmann L¹ ; Brand S^{1, 4, 5, 6, 7} ; Beglinger C⁸ ; Borgwardt S^{1, 9} ; Raes J^{2, 3} ; Schmidt A¹ ; Lang UE¹ Show Affiliations
Source: Translational Psychiatry Published:2022

Abstract

A promising new treatment approach for major depressive disorder (MDD) targets the microbiota-gut-brain (MGB) axis, which is linked to physiological and behavioral functions affected in MDD. This is the first randomized controlled trial to determine whether short-term, high-dose probiotic supplementation reduces depressive symptoms along with gut microbial and neural changes in depressed patients. Patients with current depressive episodes took either a multi-strain probiotic supplement or placebo over 31 days additionally to treatment-as-usual. Assessments took place before, immediately after and again four weeks after the intervention. The Hamilton Depression Rating Sale (HAM-D) was assessed as primary outcome. Quantitative microbiome profiling and neuroimaging was used to detect changes along the MGB axis. In the sample that completed the intervention (probiotics N = 21, placebo N = 26), HAM-D scores decreased over time and interactions between time and group indicated a stronger decrease in the probiotics relative to the placebo group. Probiotics maintained microbial diversity and increased the abundance of the genus Lactobacillus, indicating the effectivity of the probiotics to increase specific taxa. The increase of the Lactobacillus was associated with decreased depressive symptoms in the probiotics group. Finally, putamen activation in response to neutral faces was significantly decreased after the probiotic intervention. Our data imply that an add-on probiotic treatment ameliorates depressive symptoms (HAM-D) along with changes in the gut microbiota and brain, which highlights the role of the MGB axis in MDD and emphasizes the potential of microbiota-related treatment approaches as accessible, pragmatic, and non-stigmatizing therapies in MDD. Trial Registration: www.clinicaltrials.gov, identifier: NCT02957591. © 2022, The Author(s).